Evidence map›Paper›PMID 39330014›Full record

ArticleCurrent oncology (Toronto, Ont.)2024

A Customized 3D-Printed Bolus for High-Risk Breast Cancer with Skin Infiltration: A Pilot Study.

Silvia Takanen, Anna Ianiro, Paola Pinnarò, Erminia Infusino, Laura Marucci, Antonella Soriani, Giuseppe Sanguineti, Giuseppe Iaccarino

Abstract readCase Reports
In one paragraph

Article in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Clinical application of 3D-printed bolus in postmastectomy radiotherapy.Journal of applied clinical medical physics · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Silvia TakanenRadiation Oncology Department, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.ORCID 0000-0002-8510-4188
Anna IaniroMedical Physics Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.ORCID 0000-0001-6870-5507
Paola PinnaròRadiation Oncology Department, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
Erminia InfusinoMedical Physics Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
Laura MarucciRadiation Oncology Department, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
Antonella SorianiMedical Physics Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.ORCID 0000-0002-2795-5603
Giuseppe SanguinetiRadiation Oncology Department, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
Giuseppe IaccarinoMedical Physics Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn high-risk breast cancer patients with skin infiltration, the administration of a uniform dose to superficial tissues is fundamental in order to reduce local skin relapse. A personalized bolus may prevent the potential inadequate dose distribution of a standard bolus due to air gaps between the bolus and the skin. In this pilot study, we introduced into clinical practice the use of a personalized 3D-printed bolus filled with ultrasound transmission gel.

methodsSeven patients undergoing radiotherapy after mastectomy were selected. A 3D-printed bolus dosimetric assessment was performed with MOSFET dosimeters on an anthropomorphic phantom and, subsequently, on three selected cases with increasing bolus shape irregularity. Acute/late toxicity and local control were assessed.

resultsOverall, for the clinical cases, the percentage median difference between the measured and calculated doses was -2.7% (-7.0-4.9%). The median follow-up was 21 months. After two years, one patient showed G2 pain, one patient manifested G1 telangiectasia, one patient showed G1 hyperpigmentation, and two patients had no relevant toxicity.

conclusionsA personalized 3D-printed bolus filled with ultrasound gel may easily reproduce the standard bolus' consistency and provide accurate coverage of the target area with tolerable acute/late toxicity grades. This is a pilot study, and further investigations are needed.

Indexed as

Breast NeoplasmsPrinting, Three-DimensionalAdultAgedFemaleHumansMiddle AgedPilot ProjectsRadiotherapy DosageSkin3D-printed bolusbreast cancerdosimetric analysisskin toxicity

Identifiers

PMID39330014
PMCPMC11431794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.